2 Oct 2026, 16:16
Meetings & Governance—
OCCORTHOCELL LIMITED
Announcement history available from 1 August 2025
Fromto
2 Oct 2026, 11:04
Other—
21 Sept 2026, 08:55
Company UpdateMS
11 Sept 2026, 15:14
Securities Administration—
11 Sept 2026, 15:08
Securities Administration—
10 Sept 2026, 08:30
Meetings & Governance—
31 Aug 2026, 12:57
Company Administration—
31 Aug 2026, 12:57
Company Administration—
31 Aug 2026, 12:56
Financial ResultsMS
12 Aug 2026, 08:27
Presentations—
11 Aug 2026, 08:45
Presentations—
3 Aug 2026, 08:38
Securities Administration—
20 July 2026, 18:10
Director Interests—
20 July 2026, 18:06
Securities Administration—
17 July 2026, 16:42
Director Interests—
17 July 2026, 16:36
Securities Administration—
17 July 2026, 13:31
Securities Administration—
17 July 2026, 13:30
Securities Administration—
17 July 2026, 10:07
Securities Administration—
17 July 2026, 10:03
Securities Administration—
16 July 2026, 13:43
Securities Administration—
14 July 2026, 08:47
PresentationsMS
13 July 2026, 08:53
Quarterly ReportsMS
6 July 2026, 08:43
Periodic Reports—
3 July 2026, 08:56
Company UpdateMS
30 June 2026, 08:51
Company Update—
14 May 2026, 16:15
Securities Administration—
14 May 2026, 16:11
Securities Administration—
5 May 2026, 16:22
Securities Administration—
5 May 2026, 16:19
Securities Administration—
4 May 2026, 09:39
Director Interests—
4 May 2026, 09:36
Director Interests—
30 Apr 2026, 09:14
Company UpdateMS
28 Apr 2026, 09:10
Company UpdateMS
20 Apr 2026, 09:05
PresentationsMS
20 Apr 2026, 09:04
Quarterly ReportsMS
17 Apr 2026, 09:01
Company UpdateMS
15 Apr 2026, 09:00
Company UpdateMS
15 Apr 2026, 08:25
Securities Administration—
14 Apr 2026, 10:20
Presentations—
8 Apr 2026, 09:06
Company Administration—
31 Mar 2026, 14:43
Presentations—
18 Mar 2026, 09:57
Company UpdateMS
16 Mar 2026, 19:29
Securities Administration—
16 Mar 2026, 18:34
Securities Administration—
10 Mar 2026, 09:08
Company UpdateMS
26 Feb 2026, 08:47
Director Interests—
26 Feb 2026, 08:46
Director Interests—
24 Feb 2026, 09:02
Financial ResultsMS
18 Feb 2026, 12:56
Periodic ReportsMS
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 2 Oct 2026, 16:16 | Letter to Shareholders, Notice of AGM & Proxy Form | Meetings & Governance | — | 08001, 08004, 16002 | |
| 2 Oct 2026, 11:04 | Change of Auditor | Other | — | 12018 | |
| 21 Sept 2026, 08:55 | Orthocell Achieves First Remplir Sales in Thailand | Company Update | MS | 11001 | |
| 11 Sept 2026, 15:14 | Cleansing Notice | Securities Administration | — | 06018 | |
| 11 Sept 2026, 15:08 | Application for quotation of securities - OCC | Securities Administration | — | 06020 | |
| 10 Sept 2026, 08:30 | Date of AGM & Closing Date for Director Nominations | Meetings & Governance | — | 08006 | |
| 31 Aug 2026, 12:57 | Appendix 4G | Company Administration | — | 03025 | |
| 31 Aug 2026, 12:57 | Corporate Governance Statement | Company Administration | — | 03024 | |
| 31 Aug 2026, 12:56 | Appendix 4E & Annual Report | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 12 Aug 2026, 08:27 | Orthocell Canaccord Genuity Conference Live Webcast | Presentations | — | 14014 | |
| 11 Aug 2026, 08:45 | Orthocell to Present at Canaccord Growth Conference | Presentations | — | 03026 | |
| 3 Aug 2026, 08:38 | Change of Registered Office & Principal Place of Business | Securities Administration | — | 12002, 12003 | |
| 20 July 2026, 18:10 | Appendix 3Y - John Van Der Wielen | Director Interests | — | 02009 | |
| 20 July 2026, 18:06 | Application for quotation of securities - OCC | Securities Administration | — | 06020 | |
| 17 July 2026, 16:42 | Appendix 3Y x 4 | Director Interests | — | 02009 | |
| 17 July 2026, 16:36 | Application for quotation of securities - OCC | Securities Administration | — | 06020 | |
| 17 July 2026, 13:31 | Notification regarding unquoted securities - OCC | Securities Administration | — | 06021 | |
| 17 July 2026, 13:30 | Notification regarding unquoted securities - OCC | Securities Administration | — | 06021 | |
| 17 July 2026, 10:07 | Option Terms and Conditions | Securities Administration | — | 06009 | |
| 17 July 2026, 10:03 | Proposed issue of securities - OCC | Securities Administration | — | 06013 | |
| 16 July 2026, 13:43 | Notification of cessation of securities - OCC | Securities Administration | — | 06027 | |
| 14 July 2026, 08:47 | Q4 FY26 ASX Investor Presentation | Presentations | MS | 03026, 19009 | |
| 13 July 2026, 08:53 | Quarterly Activity Report & Appendix 4C | Quarterly Reports | MS | 19004, 19009 | |
| 6 July 2026, 08:43 | Orthocell Investor Webinar Details | Periodic Reports | — | 03027 | |
| 3 July 2026, 08:56 | Orthocell Appoints Thailand Distributor for Remplir | Company Update | MS | 11001 | |
| 30 June 2026, 08:51 | Clinical Outcomes See Expanded Use of Remplir in the Ukraine | Company Update | — | 11001 | |
| 14 May 2026, 16:15 | Cleansing Notice | Securities Administration | — | 06018 | |
| 14 May 2026, 16:11 | Application for quotation of securities - OCC | Securities Administration | — | 06020 | |
| 5 May 2026, 16:22 | Cleansing Notice | Securities Administration | — | 06018 | |
| 5 May 2026, 16:19 | Application for quotation of securities - OCC | Securities Administration | — | 06020 | |
| 4 May 2026, 09:39 | Appendix 3Y - Michael McNulty | Director Interests | — | 02009 | |
| 4 May 2026, 09:36 | Appendix 3Y - John Van Der Wielen | Director Interests | — | 02009 | |
| 30 Apr 2026, 09:14 | First Sales of Remplir Achieved in US$75m Canadian Market | Company Update | MS | 11001 | |
| 28 Apr 2026, 09:10 | Compelling 90% Success Rate for Remplir in Real World Study | Company Update | MS | 11001 | |
| 20 Apr 2026, 09:05 | Q3 FY26 Investor Presentation | Presentations | MS | 03026 | |
| 20 Apr 2026, 09:04 | Quarterly Activity Report & Appendix 4C | Quarterly Reports | MS | 19003, 19008 | |
| 17 Apr 2026, 09:01 | First Surgical Use of Remplir in US Department of Defense | Company Update | MS | 11001 | |
| 15 Apr 2026, 09:00 | OCC Secures Access to 221 U.S. Military Medical Centres | Company Update | MS | 11001 | |
| 15 Apr 2026, 08:25 | Notification of cessation of securities - OCC | Securities Administration | — | 06027 | |
| 14 Apr 2026, 10:20 | Orthocell Investor Webinar Details | Presentations | — | 03027, 14014 | |
| 8 Apr 2026, 09:06 | US Section 232 Tariffs Not Expected to Affect Remplir | Company Administration | — | 12008 | |
| 31 Mar 2026, 14:43 | Orthocell Investor Presentation - Broker Meets Biotech | Presentations | — | 03026 | |
| 18 Mar 2026, 09:57 | Remplir Used in 23 Surgeries in Ukrainian soldiers | Company Update | MS | 11001 | |
| 16 Mar 2026, 19:29 | Notification of cessation of securities - OCC | Securities Administration | — | 06027 | |
| 16 Mar 2026, 18:34 | Notification regarding unquoted securities - OCC | Securities Administration | — | 06021 | |
| 10 Mar 2026, 09:08 | Orthocell Appoints UK Distributor for Remplir | Company Update | MS | 11001 | |
| 26 Feb 2026, 08:47 | Appendix 3Y - Michael McNulty | Director Interests | — | 02009 | |
| 26 Feb 2026, 08:46 | Appendix 3Y - John Van Der Wielen | Director Interests | — | 02009 | |
| 24 Feb 2026, 09:02 | Appendix 4D & Half-Year Financial Report | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 18 Feb 2026, 12:56 | Orthocell Receives $3.0m R&D Tax Refund | Periodic Reports | MS | 03014 |
1–50 of 104
1 / 3